Lv1
20 积分 2023-11-13 加入
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
1小时前
待确认
Antidotes for Anticoagulation Reversal
1天前
已完结
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
15天前
已完结
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
2个月前
已完结
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
3个月前
已完结
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
3个月前
已完结
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
3个月前
已完结
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML
3个月前
已完结
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial
3个月前
已完结
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
3个月前
已完结
皖公网安备34019202002308
